Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
163 hedge funds and large institutions have $1.11B invested in Esperion Therapeutics in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 22 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 41
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
4% more funds holding
Funds holding: 156 → 163 (+7)
2.9% more ownership
Funds ownership: 100.01% → 102.91% (+2.9%)
10% less capital invested
Capital invested by funds: $1.23B → $1.11B (-$125M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
47% less call options, than puts
Call options by funds: $14M | Put options by funds: $26.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.74M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.98M |
| 3 |
Renaissance Technologies
New York
|
+$7.97M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.58M |
| 5 |
Millennium Management
New York
|
+$7.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$11.3M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$10.1M |
| 3 |
Citigroup
New York
|
-$10.1M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.21M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.18M |
ESPR Hedge Fund Activity: Q1 2019 in Review
163 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2019, worth a combined $1.11B — down 10% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ESPR positions and 22 closed out — a net gain of 7 holders — while 59 added to existing stakes and 41 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $9.74M. The largest seller was PFM Health Sciences, cutting an estimated $11.3M.
- 163 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2019, up from 156 in Q4 2018.
- Funds reported $1.11B of Esperion Therapeutics stock for Q1 2019, down 10% quarter-over-quarter.
- 29 funds opened new Esperion Therapeutics positions in Q1 2019 and 22 closed out, a net change of +7 holders.
- The largest Esperion Therapeutics buyer in Q1 2019 was Point72 Asset Management, an estimated $9.74M added.
- The largest Esperion Therapeutics seller in Q1 2019 was PFM Health Sciences, an estimated $11.3M sold.
Based on aggregated 13F filings for Q1 2019.